Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review

References

• Sethi S, Glassock RJ, Fervenza FC. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant. 2015;30(3):375–384.
   PubMed Web of Science ®Google Scholar
• Campbell KN, Tumlin JA. Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol. 2018;47(Suppl 1):14–29.
   PubMedGoogle Scholar
• D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):117–134.
   PubMed Web of Science ®Google Scholar
• Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76–87.
   PubMed Web of Science ®Google Scholar
• Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis. 1993;22(6):874–883.
   PubMed Web of Science ®Google Scholar
• Shabaka A, Tato Ribera A, Fernández-Juárez G. Focal segmental glomerulosclerosis: state-of-the-Art and clinical perspective. Nephron. 2020;144(9):413–427.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Sethi S, Nath KA, et al. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. J Am Soc Nephrol. 2018;29(3):759–774.
   PubMed Web of Science ®Google Scholar
• Lepori N, Zand L, Sethi S, et al. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J. 2018;11(2):179–190.
   PubMed Web of Science ®Google Scholar
• Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012;23(11):1769–1776.
   PubMed Web of Science ®Google Scholar
• Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878–883.
   PubMed Web of Science ®Google Scholar
• Braun F, Homeyer I, Alachkar N, et al. Immune-mediated entities of (primary) focal segmental glomerulosclerosis. Cell Tissue Res. 2021;385(2):423–434.
   PubMed Web of Science ®Google Scholar
• Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates. Biomed Res Int. 2016;2016:3765608.
   PubMed Web of Science ®Google Scholar
• Canaud G, Zuber J, Sberro R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant. 2009;9(5):1081–1086.
   PubMed Web of Science ®Google Scholar
• Raina R, Wang J, Sharma A, et al. Extracorporeal therapies in the treatment of focal segmental glomerulosclerosis. Blood Purif. 2020;49(5):513–523.
   PubMed Web of Science ®Google Scholar
• Allard L, Kwon T, Krid S, et al. Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre french cohort. Nephrol Dial Transplant. 2018;33(6):954–963.
   PubMed Web of Science ®Google Scholar
• Bosch T, Wendler T. Extracorporeal plasma treatment in primary and recurrent focal segmental glomerular sclerosis: a review. Ther Apher. 2001;5(3):155–160.
   PubMedGoogle Scholar
• Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant. 1998;13(6):1524–1528.
   PubMed Web of Science ®Google Scholar
• Feld SM, Figueroa P, Savin V, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis. 1998;32(2):230–237.
   PubMed Web of Science ®Google Scholar
• Chen YY, Sun X, Huang W, et al. Therapeutic apheresis in kidney diseases: an updated review. Ren Fail. 2022;44(1):842–857.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Yamazaki J, Kanehisa E, Yamaguchi W, et al. Idiopathic collapsing focal segmental glomerulosclerosis in an 81-year-old japanese woman: a case report and review of the literature. CEN Case Rep. 2016;5(2):197–202.
   PubMedGoogle Scholar
• Schenk H, Muller-Deile J, Schmitt R, et al. Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb. J Clin Apher. 2017;32(6):444–452.
   PubMed Web of Science ®Google Scholar
• Ishii E, Ando Y, Tamba K, et al. Rapid and persistent reduction of proteinuria following plasma exchange in a case of steroid-resistant focal segmental glomerulosclerosis. Ther Apher. 2002;6(2):174–177.
   PubMedGoogle Scholar
• Kuhn C, Kuhn A, Markau S, et al. Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis. J Clin Apher. 2006;21(4):266–270.
   PubMed Web of Science ®Google Scholar
• Oliveira L, Wang D, McCormick BB. A case report of plasmapheresis and cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis: recovery of renal function after five months on dialysis. Ther Apher Dial. 2007;11(3):227–231.
   PubMed Web of Science ®Google Scholar
• Araki H, Ono S, Nishizawa Y, et al. Focal segmental glomerular sclerosis ameliorated by long-term hemodialysis therapy with low-density lipoprotein apheresis. Intern Med. 2015;54(17):2213–2217.
   PubMed Web of Science ®Google Scholar
• Yorioka N, Taniguchi Y, Nishida Y, et al. Low-density lipoprotein apheresis for focal glomerular sclerosis. Ther Apher. 1997;1(4):370–371.
   PubMedGoogle Scholar
• Ginsburg DS, Dau P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol. 1997;48(5):282–287.
   PubMed Web of Science ®Google Scholar
• Cader RA, Kang TM. Plasmapheresis in refractory FSGS. J Clin Nephrol Res. 2017;4(4):1072.
   Google Scholar
• Muso E, Mune M, Hirano T, et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS study. Clin Exp Nephrol. 2015;19(3):379–386.
   PubMed Web of Science ®Google Scholar
• Dirim AB, Demir E, Guller N, et al. Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis. J Clin Apher. 2022;37(4):376–387.
   PubMed Web of Science ®Google Scholar
• Moriconi L, Lenti C, Puccini R, et al. Proteinuria in focal segmental glomerulosclerosis: role of circulating factors and therapeutic approach. Ren Fail. 2001;23(3-4):533–541.
   PubMed Web of Science ®Google Scholar
• Haas M, Godfrin Y, Oberbauer R, et al. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant. 1998;13(8):2013–2016.
   PubMed Web of Science ®Google Scholar
• Muso E, Mune M, Hirano T, et al. A prospective observational survey on the Long-Term effect of LDL apheresis on Drug-Resistant nephrotic syndrome. Nephron Extra. 2015;5(2):58–66.
   PubMed Web of Science ®Google Scholar
• Muso E, Mune M, Fujii Y, et al. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis treatment (K-FLAT) Study group. Kidney Int Suppl. 1999;71: s 122–5.
   Google Scholar
• Yokoyama H, Shimizu M, Wada T, et al. The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome. Ther Apher. 2002;6(2):167–173.
   PubMedGoogle Scholar
• Banfi G, Moriggi M, Sabadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991;36(2):53–59.
   PubMed Web of Science ®Google Scholar
• Braden GL, Mulhern JG, O'Shea MH, et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis. 2000;35(5):878–883.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in olmsted county, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol. 2006;1(3):483–487.
   PubMed Web of Science ®Google Scholar
• Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis. 1994;23(6):773–783.
   PubMed Web of Science ®Google Scholar
• Wehrmann M, Bohle A, Held H, et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol. 1990;33(3):115–122.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev. 2018;17(10):1022–1027.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Alvestrand A, Angelin B, et al. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Invest. 2000;30(10):866–870.
   PubMed Web of Science ®Google Scholar
• Muso E, Mune M, Yorioka N, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol. 2007;67(6):341–344.
   PubMed Web of Science ®Google Scholar
• Ullrich H, Kuehnl P. New trends in specific immunoadsorption. Transfus Apher Sci. 2004;30(3):223–231.
   PubMed Web of Science ®Google Scholar
• Ueki Y, Yamasaki S, Kanamoto Y, et al. Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology (Oxford). 2000;39(2):165–171.
   PubMed Web of Science ®Google Scholar
• Takenaka Y. Lymphocytapheresis. Artif Organs. 1996;20(8):914–916.
   PubMed Web of Science ®Google Scholar
• Koyama A, Fujisaki M, Kobayashi M, et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991;40(3):453–460.
   PubMed Web of Science ®Google Scholar
• Godfrin Y, Dantal J, Bouhours JF, et al. A new method of measuring albumin permeability in isolated glomeruli. Kidney Int. 1996;50(4):1352–1357.
   PubMed Web of Science ®Google Scholar
• Moret L, Ganea A, Dao M, et al. Apheresis in adult with refractory idiopathic nephrotic syndrome on native kidneys. Kidney Int Rep. 2021;6(8):2134–2143.
   PubMed Web of Science ®Google Scholar
• Muso E, Mune M, Fujii Y, Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group, et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 2001;89(4):408–415.
   PubMed Web of Science ®Google Scholar
• Honore PM, Jacobs R, De Waele E, et al. Immunoadsorption versus therapeutic plasma exchange. Will fibrinogen make the difference? Blood Purif. 2014;38(2):158–159.
   PubMed Web of Science ®Google Scholar